

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Berka et al.

Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: March 22, 2000

Examiner: To Be Assigned

For: Methods For Monitoring Multiple Gene Expression



TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Information Disclosure Statement for the above-identified application. Should it be determined that a fee is due, please charge it to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: March 22, 2000

A handwritten signature in cursive script, reading "Robert L. Starnes", is written over a horizontal line.

Robert L. Starnes, Reg. No. 41,324
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, New York 10017
(212)867-0123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Berka *et al.*

Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: March 22, 2000

Examiner: To Be Assigned

For: Methods For Monitoring Multiple Gene Expression

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231



Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.


The references are as follows:

1. Watson et al., 1998, Current Opinion in Biotechnology 9: 609-614
2. Chu et al., 1998, Science 282: 699-705
3. Ruan et al., 1998, The Plant Journal 15: 821-833
4. Iyer et al., 1999, Science 283: 83-87
5. Hayward et al., 2000, Molecular Microbiology 35: 6-14

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Respectfully submitted,

Date: March 22, 2000

A handwritten signature in cursive script, reading "Robert L. Starnes". The signature is written in dark ink and is positioned above a horizontal line.

Robert L. Starnes, Reg. No. 41,324
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123